^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RASSF1 methylation

    i
    Other names: RASSF1, Ras Association Domain Family Member 1, RDA32, Pancreas-Specific Ras Association Domain Family 1 Protein, Cardiac-Specific Ras Association Domain Family 1 Protein, Ras Association Domain-Containing Protein 1, REH3P21 , NORE2A
    Entrez ID:
    11186
    1year
    Association of DNA methylation of RASSF1A and SHOX2 with lung cancer risk: A systematic review and meta-analysis. (PubMed, Medicine (Baltimore))
    RASSF1A and SHOX2 DNA methylation may emerge as potential diagnostic biomarkers for early-stage LC.
    Clinical • Retrospective data • Review • Journal • Epigenetic controller
    |
    RASSF1 (Ras Association Domain Family Member 1) • SHOX2 (SHOX Homeobox 2)
    |
    RASSF1 methylation
    1year
    Aberrant promoter methylation, expression and function of RASSF1A gene in a series of Italian parathyroid tumors. (PubMed, Endocrine)
    RASSF1A and APC promoter methylation is a hallmark of parathyroid tumors; deregulation of DNMTs activity contributes to modulation of RASSF1A expression. Loss of RASSF1A may be involved in the tuning of ERK pathway in parathyroid tumors.
    Journal
    |
    RASSF1 (Ras Association Domain Family Member 1)
    |
    RASSF1 methylation
    over1year
    Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment. (PubMed, Front Oncol)
    AXL and PIM-1 expression detected in CTCs during treatment suggesting new possible therapeutic strategies. Our results reveal that comprehensive liquid biopsy analysis can efficiently represent the heterogeneous molecular landscape and provide prominent information on subsequent treatments for NSCLC patients at PD since druggable molecular alterations were detected in CTCs.
    Journal • Liquid biopsy • PD(L)-1 Biomarker • IO biomarker • Biopsy
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • B2M (Beta-2-microglobulin) • FOXA1 (Forkhead Box A1) • PIM1 (Pim-1 Proto-Oncogene) • VIM (Vimentin) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • KRT19 (Keratin 19) • RASSF1 (Ras Association Domain Family Member 1) • WIF1 (WNT Inhibitory Factor 1) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator)
    |
    PD-L1 expression • BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • EGFR T790M • MET mutation • KRAS G12 • EGFR mutation + PIK3CA mutation • HER-2 amplification + PD-L1 expression • VIM expression • HER-2 amplification + MET amplification • RASSF1 methylation
    |
    Tagrisso (osimertinib)
    almost2years
    Circulating tumor DNA and its role in detection, prognosis and therapeutics of hepatocellular carcinoma. (PubMed, Chin J Cancer Res)
    This article overviews many conditions in genetic changes linked to the onset and development of HCC, such as dysregulated signaling pathways, somatic mutations, single-nucleotide polymorphisms, and genomic instability. Additionally, efforts are also made to develop treatments for HCC that are molecularly targeted and to unravel some of the genetic pathways that facilitate its early identification.
    Journal • Circulating tumor DNA
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • KMT2C (Lysine Methyltransferase 2C) • CDK6 (Cyclin-dependent kinase 6) • CCNA2 (Cyclin A2) • AXIN1 (Axin 1) • RASSF1 (Ras Association Domain Family Member 1) • SEPTIN9 (Septin 9)
    |
    BRAF mutation • KRAS deletion • RASSF1 methylation
    almost2years
    Endometrial Cancer Detection by DNA Methylation Analysis in Cervical Papanicolaou Brush Samples. (PubMed, Technol Cancer Res Treat)
    These findings demonstrate that DNA methylation analysis in cervical Pap brush samples may be helpful for EC detection, broadening the scope of the commonly used cytological screening. Our proof-of-concept study provides new insights into the field of clinical EC diagnosis.
    Journal • Epigenetic controller
    |
    RASSF1 (Ras Association Domain Family Member 1)
    |
    RASSF1 methylation
    almost2years
    Methylation study of tumor suppressor genes in human aberrant crypt foci, colorectal carcinomas, and normal colon. (PubMed, J Cancer Res Ther)
    Early epigenetic methylation of WIF1 gene is one of the mechanisms for ACF development in human colon.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MLH1 (MutL homolog 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CD44 (CD44 Molecule) • RASSF1 (Ras Association Domain Family Member 1) • WIF1 (WNT Inhibitory Factor 1)
    |
    CD44 expression • CD44 positive • RASSF1 methylation
    almost2years
    Diagnostic Value of GSTP1, RASSF1, AND RASSF2 Methylation in Serum of Prostate Cancer Patients. (PubMed, Urol J)
      Although we observed that the GSTP1 and RASSF1 methylation positivity rates that we examined in our study were higher in patients without prostate cancer, we found that the RASSF2 methylation rate was higher in patients with prostate cancer. randomized controlled studies are needed.
    Journal
    |
    GSTP1 (Glutathione S-transferase pi 1) • RASSF1 (Ras Association Domain Family Member 1)
    |
    RASSF1 methylation
    almost2years
    Evaluating the comprehensive diagnosis efficiency of lung cancer, including measurement of SHOX2 and RASSF1A gene methylation. (PubMed, BMC Cancer)
    Finally, we present a comprehensive lung cancer diagnostic work-up, including LumgMe® methylation. The combined analysis of SHOX2 and RASSF1A methylation serves as a powerful complement and extension to conventional methods, enhancing the accuracy of a lung cancer diagnosis with satisfactory sensitivity and specificity.
    Journal
    |
    RASSF1 (Ras Association Domain Family Member 1) • SHOX2 (SHOX Homeobox 2)
    |
    RASSF1 methylation
    almost2years
    Influential factors on urine EV DNA methylation detection and its diagnostic potential in prostate cancer. (PubMed, Front Genet)
    Our results suggest the potential of urine EV DNA as a novel marker for PCa diagnosis. This provides a new idea for the study of urinary tumor markers.
    Journal • Epigenetic controller
    |
    RASSF1 (Ras Association Domain Family Member 1)
    |
    RASSF1 methylation
    2years
    The combination of SHOX2 and RASSF1A DNA methylation had a diagnostic value in pulmonary nodules and early lung cancer. (PubMed, Oncology)
    The combination of SHOX2 and RASSF1A DNA methylation had a diagnostic value in pulmonary nodules and early LC. SHOX2 positively modulated the tumorigenesis and metastasis of LC by regulating DNA methylation processes.
    Journal • Epigenetic controller
    |
    RASSF1 (Ras Association Domain Family Member 1) • SHOX2 (SHOX Homeobox 2)
    |
    RASSF1 methylation
    |
    azacitidine
    2years
    SEPT9, H4C6, and RASSF1A methylation in nasopharyngeal swabs: A reflection of potential minimally invasive biomarkers for early screening of nasopharyngeal cancer. (PubMed, Medicine (Baltimore))
    The diagnostic ability of dual gene combination is better than that of single gene combination, among which SEPT9 and H4C6 combination has the best diagnostic effect. In conclusion, our findings suggest that H4C6, RASSF1A, and SEPT9 methylation occur more frequently in nasopharyngeal carcinoma, and their detection in nasopharyngeal swabs may be a minimally invasive tool for diagnosis of nasopharyngeal carcinoma.
    Journal
    |
    GSTP1 (Glutathione S-transferase pi 1) • SOX2 • RASSF1 (Ras Association Domain Family Member 1) • SEPTIN9 (Septin 9) • SHOX2 (SHOX Homeobox 2)
    |
    RASSF1 methylation
    2years
    RASSF1A promotes ATM signaling and RASSF1A methylation is a synthetic lethal marker for ATR inhibitors. (PubMed, Epigenomics)
    Loss of RASSF1A expression sensitized esophageal cancer cell lines to ataxia telangiectasia mutated and rad3-related (ATR) inhibitor (VE-822) both in vitro and in vivo. RASSF1A methylation is a synthetic lethal marker for ATR inhibitors.
    Journal • Synthetic lethality
    |
    RASSF1 (Ras Association Domain Family Member 1)
    |
    RASSF1 methylation
    |
    berzosertib (M6620)